Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia

Logos of Chugai and Alebund

Chugai Pharmaceutical Co., Ltd.
Alebund Pharmaceuticals (Hong Kong) Limited

  • Chugai and Alebund enter into an option and license agreement regarding EOS789, an investigational drug for hyperphosphatemia, discovered by Chugai
  • If Alebund decides to exercise the option, Chugai will grant to Alebund an exclusive license to develop, manufacture, and commercialize EOS789 worldwide including Japan

TOKYO, JAPAN and SHANGHAI, CHINA, July 9, 2021 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Alebund Pharmaceuticals (Hong Kong) Limited, announced that they have entered into an option and license agreement regarding Chugai’s EOS789, an investigational agent under development for hyperphosphatemia.

Continue reading Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia